Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors

American Heart Journal

Volumn 163, Issue 2, 2012, Pages 156-163

  Steingart, Richard M ^a   Bakris, George L ^b   Chen, Helen X ^c   Chen, Ming Hui ^d   Force, Thomas ^e   Ivy, S Percy ^c   Leier, Carl V ^f   Liu, Glenn ^g   Lenihan, Daniel ^h   Lindenfeld, Joann ⁱ   Maitland, Michael L ^b   Remick, Scot C ^j   Tang, W H Wilson ^k  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF WISCONSIN   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PAZOPANIB; RIFAMPICIN; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN INHIBITOR;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD PRESSURE MONITORING; BRAIN ISCHEMIA; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TORSADE DES POINTES;

EID: 84863041902     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.10.018     Document Type: Review

References (28)

1. M.L. Maitland, G.L. Bakris, and H.R. Black Initial assessment, surveillance and management of blood pressure in patients receiving vascular endothelial growth factor pathway inhibitors J Natl Cancer Inst 102 2010 596 604
2. M.L. Telli, R.M. Witteles, and G.A. Fisher Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Ann Oncol 19 2008 1613 1618
3. T.E. Hutson, R.A. Figlin, and J.G. Kuhn Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies The Oncologist 13 2008 1084 1096
4. T. Force, D.S. Krause, and R.A. Van Etten Molecular mechanism of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 2007 332 344 (Pubitemid 46652481)
5. Sutent (sunitinib malate) capsules [package insert] 2008 Pfizer Labs New York, NY
6. Votrient (pazopanib) tablets. Highlights of prescribing information 2010 GlaxoSmithKline Research Triangle Park, NC
7. Caprelsa (vandetanib) tablets. Highlights of prescribing informations 2011 Astra Zeneca Wilmington, DE
8. Avastin (bevacizumab) solution for intravenous infusion [package insert] 2009 Genentech, Inc South San Francisco, CA
9. Nexavar (sorafenib) tablets [package insert] 2008 Bayer Healthcare Pharmaceuticals Inc Wayne, NJ
10. Y. Izumiya, I. Shiojima, and K. Sato Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload Hypertension 47 2006 887 893 (Pubitemid 44297560)
11. V. Chintalgattu, D. Ai, and R.R. Langley Cardiomyocyte PDGRF-β signaling is an essential component of mouse cardiac response to load-induced stress J Clin Invest 120 2010 472 484
12. M.H. Chen, R. Kerkelä, and T. Force Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics Circulation 118 2008 84 95
13. T. Force, and R. Kerkela Cardiotoxicity of the new cancer therapeutics-mechanisms of, and approaches to, the problem Drug Discov Today 13 2008 778 784
14. G. Mancia, G. De Backer, and A. Dominiczak Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 2007 28 2007 1462 1536
15. S. Sleijfer, I. Ray-Coquard, and Papai Zsuzsa Pazopanib, a multikinase inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma J Clin Oncol 27 2009 3126 3132
16. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
17. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2242 2250
18. K.D. Miller, L.I. Chap, and F.A. Holmes Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 2005 792 799 (Pubitemid 46224178)
19. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
20. F.A. Scappaticci, J.R. Skillings, and S.N. Holden Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239 (Pubitemid 47299901)
21. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
22. T.F. Chu, M.A. Rupnick, and R. Kerkela Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019 (Pubitemid 350236338)
23. A.Y. Khakoo, C.M. Kassiotis, and N. Tannir Heart failure associated with sunitinib malate Cancer 112 2008 2500 2508
24. M. Schmidinger, C.C. Zielinski, and U.M. Vogl Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 2008 5204 5212
25. B. Escudier, T. Eisen, and W.M. Stabler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
26. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
27. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
28. T.E. Hutson, I.D. Davis, and J.P. Machiels Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma J Clin Oncol 28 2010 475 480